1. Home
  2. NNVC vs LNAI Comparison

NNVC vs LNAI Comparison

Compare NNVC & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.15

Market Cap

24.4M

Sector

Health Care

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.92

Market Cap

22.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NNVC
LNAI
Founded
2005
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.4M
22.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NNVC
LNAI
Price
$1.15
$0.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
273.7K
154.2K
Earning Date
02-13-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.81
52 Week High
$2.23
$14.00

Technical Indicators

Market Signals
Indicator
NNVC
LNAI
Relative Strength Index (RSI) 44.86 N/A
Support Level $1.13 N/A
Resistance Level $1.21 N/A
Average True Range (ATR) 0.07 0.00
MACD 0.00 0.00
Stochastic Oscillator 15.00 0.00

Price Performance

Historical Comparison
NNVC
LNAI

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: